ABO Blood Group IgM Isoagglutinins Interact with Tumor-Associated O-Glycan Structures in Pancreatic Cancer

Purpose: The ABO gene locus is associated with the risk of developing pancreatic ductal adenocarcinoma (PDAC) resulting in an increased incidence in individuals with non-O blood groups. Up to 90% of PDAC specimens display alterations in mucin type O-GalNAc glycosylation. Because aberrant O-GalNAc glycans (Tn and T antigen) are structurally related to blood group A and B glycans, we investigated the role of IgM isoagglutinins in PDAC. Experimental Design: Binding studies of IgM isoagglutinins toward blood group A, B, Tn antigen, and T antigen glycoconjugates from patients with PDAC and healthy individuals were conducted. Isoagglutinin titers and total IgM were compared between patients with PDAC and control group. An anti-A antibody was used for immunoprecipitation of aberrant O-glycosylated tumor proteins and subsequent mass spectromic analysis. Results: We found that IgM isoagglutinins bind blood group antigens, Tn and T glycoconjugates as well as tumor-derived glycoproteins. Blood group A isoagglutinins exhibited a strong binding toward blood group B antigen and T antigen, whereas blood group B showed binding to blood group A antigen and Tn antigen. Furthermore, we confirmed a decreased frequency in individuals with blood group O and observed a significant decrease of IgM isoagglutinin titers in PDAC sera compared with control sera, whereas total IgM levels were unaltered. We identified new PDAC-derived O-GalNAc glycoproteins by mass spectrometry using a blood group A-specific antibody. Conclusion: Our data elucidated a novel interaction of blood group IgM isoagglutinins and PDAC O-GalNAc glycoproteins that may contribute to the pathogenesis and progression of pancreatic cancer. Clin Cancer Res; 20(23); 6117–26. ©2014 AACR.

[1]  H. Klein,et al.  Mollison's Blood Transfusion in Clinical Medicine , 2014 .

[2]  David F. Smith,et al.  Tn and sialyl‐Tn antigens, aberrant O‐glycomics as human disease markers , 2013, Proteomics. Clinical applications.

[3]  Kristiaan J. Lenos,et al.  Human T Cell Activation Results in Extracellular Signal-regulated Kinase (ERK)-Calcineurin-dependent Exposure of Tn Antigen on the Cell Surface and Binding of the Macrophage Galactose-type Lectin (MGL)* ♦ , 2013, The Journal of Biological Chemistry.

[4]  S. Brunak,et al.  Precision mapping of the human O‐GalNAc glycoproteome through SimpleCell technology , 2013, The EMBO journal.

[5]  A. Niendorf,et al.  Protein Domain Histochemistry (PDH) , 2013, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  M. Koch,et al.  AB0 blood group and prognosis in patients with pancreatic cancer , 2012, BMC Cancer.

[7]  H. Wandall,et al.  Mining the O-glycoproteome using zinc-finger nuclease–glycoengineered SimpleCell lines , 2011, Nature Methods.

[8]  Qiwen Ben,et al.  Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: A case–control study , 2011, International journal of cancer.

[9]  R. Brand,et al.  Significant association between ABO blood group and pancreatic cancer. , 2010, World journal of gastroenterology.

[10]  P. Vogt,et al.  Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α , 2010, Proceedings of the National Academy of Sciences.

[11]  K. Pantel,et al.  Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. , 2010, Journal of proteome research.

[12]  Geoffrey S. Tobias,et al.  Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. , 2010, Cancer research.

[13]  Geoffrey S. Tobias,et al.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer , 2009, Nature Genetics.

[14]  S. Chanock,et al.  ABO blood group and the risk of pancreatic cancer. , 2009, Journal of the National Cancer Institute.

[15]  C. Hung,et al.  Does immunosuppressive pharmacotherapy affect isoagglutinin titers? , 2008, Transplantation proceedings.

[16]  B. Xia,et al.  Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. , 2008, Cancer research.

[17]  I. Brockhausen,et al.  Mucin‐type O‐glycans in human colon and breast cancer: glycodynamics and functions , 2006, EMBO reports.

[18]  A. Helenius,et al.  Roles of N-linked glycans in the endoplasmic reticulum. , 2004, Annual review of biochemistry.

[19]  J. Lowe,et al.  Role of glycosylation in development. , 2003, Annual review of biochemistry.

[20]  S. Crawley,et al.  Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. , 2002, Gastroenterology.

[21]  R. Dwek,et al.  Glycosylation and the immune system. , 2001, Science.

[22]  J. Gordon,et al.  Glycans as legislators of host-microbial interactions: spanning the spectrum from symbiosis to pathogenicity. , 2001, Glycobiology.

[23]  A. Nanashima,et al.  High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas. , 1999, Journal of hepato-biliary-pancreatic surgery.

[24]  Carolyn R. Bertozzi,et al.  Essentials of Glycobiology , 1999 .

[25]  T. Terada,et al.  Expression of mucin carbohydrate antigens (T, Tn and sialyl Tn) and MUC-1 gene product in intraductal papillary-mucinous neoplasm of the pancreas. , 1996, American journal of clinical pathology.

[26]  J. Wieruszeski,et al.  The glycan moiety of human pancreatic lithostathine. Structure characterization and possible pathophysiological implications. , 1995, European journal of biochemistry.

[27]  J. Wieruszeski,et al.  The Glycan Moiety of Human Pancreatic Lithostathine , 1995 .

[28]  R. Cummings,et al.  Presence of O-linked oligosaccharide on a threonine residue in the human transferrin receptor. , 1992, Glycobiology.

[29]  J. J. Lucas,et al.  Identification of the O-linked glycosylation site of the human transferrin receptor. , 1992, Glycobiology.

[30]  S. Hakomori,et al.  Expression of Tn, sialosyl Tn, and T antigens in human pancreas. , 1991, Gastroenterology.

[31]  M. Melamed,et al.  Blood group and blood‐group‐related antigens in normal pancreas and pancreas cancer: Enhanced expression of precursor type 1, Tn and Sialyl‐Tn in pancreas cancer , 1991, International journal of cancer.

[32]  Henrik Clausen,et al.  Molecular genetic basis of the histo-blood group ABO system , 1990, Nature.

[33]  P. Pour,et al.  Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. , 1988, Cancer research.

[34]  Y. Chung,et al.  Cancer-associated alterations of blood group antigen expression in the human pancreas. , 1987, Journal of the National Cancer Institute.

[35]  J. Cartron,et al.  Level of the A, B and H blood group glycosyltransferases in red cell membranes from patients with malignant hemopathies. , 1984, Revue francaise de transfusion et immuno-hematologie.

[36]  H. Tuppy,et al.  Microsomal Incorporation of N-Acetyl-D-galactosamine into Blood Group Substance , 1966, Nature.

[37]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[38]  Lawrence A Tabak,et al.  All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. , 2003, Glycobiology.

[39]  Maureen E. Taylor,et al.  Introduction to glycobiology , 2003 .

[40]  G J Strous,et al.  Mucin-type glycoproteins. , 1992, Critical reviews in biochemistry and molecular biology.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[42]  W. Watkins.  Biochemistry and Genetics of the ABO, Lewis, and P blood group systems. , 1980, Advances in human genetics.

[43]  W. Morgan,et al.  GENETIC AND BIOCHEMICAL ASPECTS OF HUMAN BLOOD-GROUP A−, B−, H−, Lea − AND Leb− SPECIFICITY , 1969 .